You are here

Anti-TNFα Treatment After Surgical Resection for Crohn’s Disease Is Effective Despite Previous Pharmacodynamic Failure.

Anti-TNFα Treatment After Surgical Resection for Crohn’s Disease Is Effective Despite Previous Pharmacodynamic Failure. Inflamm Bowel Dis. 2017 Feb 22;: Authors: Assa A, Bronsky J, Kolho KL, Zarubova K, de Meij T, Ledder O, Sladek M, van Biervliet S, Strisciuglio C, Shamir R Abstract BACKGROUND: The outcome of patients with Crohn’s disease who failed anti-tumor necrosis factor alpha (anti-TNFα) therapy despite adequate serum drug levels (pharmacodynamic failure) is unclear. We aimed to assess such pediatric patients who underwent intestinal resection and were re-treated with the same anti-TNFα agent postoperatively. METHODS:…

Read More

Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis.

Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2017 Feb 22;: Authors: Shah ED, Farida JP, Siegel CA, Chong K, Melmed GY Abstract BACKGROUND: The overall risk for infection with contemporary biological agents in treating Crohn’s disease (CD) and ulcerative colitis (UC) has not been systematically assessed. METHODS: We performed a PubMed and Cochrane database literature search to evaluate randomized, placebo-controlled trials of biologics in treating UC and CD. Meta-analysis was performed using a DerSimonian and Laird random…

Read More

Race Differences in Initial Presentation, Early Treatment, and 1-year Outcomes of Pediatric Crohn’s Disease: Results from the ImproveCareNow Network.

Race Differences in Initial Presentation, Early Treatment, and 1-year Outcomes of Pediatric Crohn’s Disease: Results from the ImproveCareNow Network. Inflamm Bowel Dis. 2017 Feb 20;: Authors: Dotson JL, Cho M, Bricker J, Kappelman MD, Chisolm DJ, Tomer G, Crandall WV, ImproveCareNow Pediatric IBD Learning Health System Abstract BACKGROUND: Racially disparate care has been shown to contribute to suboptimal health care outcomes for minorities. Using the ImproveCareNow network, we investigated differences in management and outcomes of pediatric patients with Crohn’s disease at diagnosis and 1-year postdiagnosis. METHODS: ImproveCareNow is a learning…

Read More

Early Transcriptomic Changes in the Ileal Pouch Provide Insight into the Molecular Pathogenesis of Pouchitis and Ulcerative Colitis.

Early Transcriptomic Changes in the Ileal Pouch Provide Insight into the Molecular Pathogenesis of Pouchitis and Ulcerative Colitis. Inflamm Bowel Dis. 2017 Mar;23(3):366-378 Authors: Huang Y, Dalal S, Antonopoulos D, Hubert N, Raffals LH, Dolan K, Weber C, Messer JS, Jabri B, Bendelac A, Eren AM, Rubin DT, Sogin M, Chang EB Abstract BACKGROUND: Ulcerative colitis (UC) only involves the colonic mucosa. Yet, nearly 50% of patients with UC who undergo total proctocolectomy with ileal pouch anal anastomosis develop UC-like inflammation of the ileal pouch (pouchitis). By contrast, patients with…

Read More

Self-managed eHealth Disease Monitoring in Children and Adolescents with Inflammatory Bowel Disease: A Randomized Controlled Trial.

Self-managed eHealth Disease Monitoring in Children and Adolescents with Inflammatory Bowel Disease: A Randomized Controlled Trial. Inflamm Bowel Dis. 2017 Mar;23(3):357-365 Authors: Carlsen K, Jakobsen C, Houen G, Kallemose T, Paerregaard A, Riis LB, Munkholm P, Wewer V Abstract BACKGROUND: To evaluate the impact of eHealth on disease activity, the need for hospital contacts, and medical adherence in children and adolescents with inflammatory bowel disease (IBD). Furthermore, to assess eHealth’s influence on school attendance and quality of life (QoL). METHODS: Patients with IBD, 10 to 17 years attending a public…

Read More

Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study.

Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study. Inflamm Bowel Dis. 2017 Mar;23(3):347-356 Authors: Poojary P, Saha A, Chauhan K, Simoes P, Sands BE, Cho J, Ullman T, Nadkarni G, Ungaro R Abstract BACKGROUND: Early readmissions are important indicators of quality of care. Limited data exist describing hospital readmissions in ulcerative colitis (UC). The aim of this study was to describe unplanned, 30-day readmissions among adult UC patients and to assess readmission predictors. METHODS: We analyzed the 2013 United States National Readmission Database…

Read More

Evidence of Bidirectional Associations Between Perceived Stress and Symptom Activity: A Prospective Longitudinal Investigation in Inflammatory Bowel Disease.

Evidence of Bidirectional Associations Between Perceived Stress and Symptom Activity: A Prospective Longitudinal Investigation in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Mar;23(3):473-483 Authors: Sexton KA, Walker JR, Graff LA, Bernstein MT, Beatie B, Miller N, Sargent M, Targownik LE Abstract BACKGROUND: Our aim was to explore the relationships among perceived stress, intestinal inflammation, and inflammatory bowel disease (IBD) symptoms over time. METHODS: Participants were recruited from a population-based registry of persons with IBD and assessed at months 0, 3, and 6. Key dependent measures were the Manitoba IBD Index…

Read More

Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis.

Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis. Inflamm Bowel Dis. 2017 Mar;23(3):409-420 Authors: Targownik LE, Tennakoon A, Leung S, Lix LM, Nugent Z, Singh H, Bernstein CN Abstract INTRODUCTION: Antitumor necrosis factor (anti-TNF) medications are known to be highly efficacious in persons with moderate-to-severe inflammatory bowel disease (IBD). There is a paucity of data from population-based sources to elucidate persistence with these medications in the general population of IBD. Discontinuation of anti-TNF therapy is a marker of lack of effectiveness, intolerance, and patient/physician…

Read More

The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn’s Disease Effector T Cells In Vivo.

The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn’s Disease Effector T Cells In Vivo. Inflamm Bowel Dis. 2017 Mar;23(3):379-391 Authors: Zundler S, Fischer A, Schillinger D, Binder MT, Atreya R, Rath T, Lopez-Pósadas R, Voskens CJ, Watson A, Atreya I, Neufert C, Neurath MF Abstract BACKGROUND: The precise mechanisms controlling homing of T effector (Teff) cells to the inflamed gut in Crohn’s disease (CD) are still unclear, and clinical outcome data from patients with inflammatory bowel disease treated with the anti-α4β7 integrin antibody vedolizumab suggest differences between…

Read More
<< Go Back